143 related articles for article (PubMed ID: 29658031)
41. Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients.
Yu Q; Huang F; Zhang M; Ji H; Wu S; Zhao Y; Zhang C; Wu J; Wang B; Pan B; Zhang X; Guo W
Mol Med Rep; 2017 Aug; 16(2):1157-1166. PubMed ID: 29067441
[TBL] [Abstract][Full Text] [Related]
42. Personalized Treatment Through Detection and Monitoring of Genetic Aberrations in Single Circulating Tumor Cells.
Tan SJ; Yeo T; Sukhatme SA; Kong SL; Lim WT; Lim CT
Adv Exp Med Biol; 2017; 994():255-273. PubMed ID: 28560679
[TBL] [Abstract][Full Text] [Related]
43. Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid.
Park S; Hur JY; Lee KY; Lee JC; Rho JK; Shin SH; Choi CM
Clin Chem Lab Med; 2017 Aug; 55(10):1489-1495. PubMed ID: 28195541
[TBL] [Abstract][Full Text] [Related]
44. A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care.
Thierry AR
Methods Mol Biol; 2016; 1392():1-16. PubMed ID: 26843041
[TBL] [Abstract][Full Text] [Related]
45. Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.
He C; Zheng L; Xu Y; Liu M; Li Y; Xu J
Clin Chim Acta; 2013 Oct; 425():119-24. PubMed ID: 23886554
[TBL] [Abstract][Full Text] [Related]
46. EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.
Liang Z; Cheng Y; Chen Y; Hu Y; Liu WP; Lu Y; Wang J; Wang Y; Wu G; Ying JM; Zhang HL; Zhang XC; Wu YL
Cancer Lett; 2017 Sep; 403():186-194. PubMed ID: 28642172
[TBL] [Abstract][Full Text] [Related]
47. Comparison of plasma and tissue samples in epidermal growth factor receptor mutation by ARMS in advanced non-small cell lung cancer.
Ma M; Shi C; Qian J; Teng J; Zhong H; Han B
Gene; 2016 Oct; 591(1):58-64. PubMed ID: 27370697
[TBL] [Abstract][Full Text] [Related]
48. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.
Rachiglio AM; Esposito Abate R; Sacco A; Pasquale R; Fenizia F; Lambiase M; Morabito A; Montanino A; Rocco G; Romano C; Nappi A; Iaffaioli RV; Tatangelo F; Botti G; Ciardiello F; Maiello MR; De Luca A; Normanno N
Oncotarget; 2016 Oct; 7(41):66595-66605. PubMed ID: 27448974
[TBL] [Abstract][Full Text] [Related]
49. Use of a new generation of capillary electrophoresis to quantify circulating free DNA in non-small cell lung cancer.
Chiappetta C; Anile M; Leopizzi M; Venuta F; Della Rocca C
Clin Chim Acta; 2013 Oct; 425():93-6. PubMed ID: 23892142
[TBL] [Abstract][Full Text] [Related]
50. A Rapid and Sensitive Method for Detection of the T790M Mutation of EGFR in Plasma DNA.
Kimura H; Nishikawa S; Koba H; Yoneda T; Sone T; Kasahara K
Adv Exp Med Biol; 2016; 924():171-174. PubMed ID: 27753039
[TBL] [Abstract][Full Text] [Related]
51. IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing.
Deans ZC; Butler R; Cheetham M; Dequeker EMC; Fairley JA; Fenizia F; Hall JA; Keppens C; Normanno N; Schuuring E; Patton SJ
Virchows Arch; 2019 Jun; 474(6):681-689. PubMed ID: 31028539
[TBL] [Abstract][Full Text] [Related]
52. [Application of Liquid Biopsy for Lung Cancer Treatment.].
Mori S; Yatabe Y
Rinsho Byori; 2016 May; 64(4):407-411. PubMed ID: 29182807
[TBL] [Abstract][Full Text] [Related]
53. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
54. Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients.
Winther-Larsen A; Demuth C; Fledelius J; Madsen AT; Hjorthaug K; Meldgaard P; Sorensen BS
Br J Cancer; 2017 Aug; 117(5):704-709. PubMed ID: 28683468
[TBL] [Abstract][Full Text] [Related]
55. Cell-free tumour DNA as a diagnostic and prognostic biomarker in non-small cell lung carcinoma.
Łochowska BA; Nowak D; Białasiewicz P
Adv Respir Med; 2019; 87(2):118-122. PubMed ID: 31038724
[TBL] [Abstract][Full Text] [Related]
56. Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients.
Kato K; Uchida J; Kukita Y; Kumagai T; Nishino K; Inoue T; Kimura M; Oba S; Imamura F
Sci Rep; 2016 Jul; 6():29093. PubMed ID: 27381430
[TBL] [Abstract][Full Text] [Related]
57. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
[TBL] [Abstract][Full Text] [Related]
58. A mutation-sensitive switch assay to detect five clinically significant epidermal growth factor receptor mutations.
Liu B; Zhou L; Wang Q; Li K
Genet Test Mol Biomarkers; 2015 Jun; 19(6):316-23. PubMed ID: 25918867
[TBL] [Abstract][Full Text] [Related]
59. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
Pi C; Zhang MF; Peng XX; Zhang YC; Xu CR; Zhou Q
Expert Rev Mol Diagn; 2017 Dec; 17(12):1089-1096. PubMed ID: 29057681
[TBL] [Abstract][Full Text] [Related]
60. Rapid isolation of cfDNA from large-volume whole blood on a centrifugal microfluidic chip based on immiscible phase filtration.
Hu F; Li J; Peng N; Li Z; Zhang Z; Zhao S; Duan M; Tian H; Li L; Zhang P
Analyst; 2019 Jul; 144(14):4162-4174. PubMed ID: 31166335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
